Innovation Provides Update on Ph II Trial of Brilacidin for Severe Oral Mucositis in Head and Neck Cancer

Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), announced on 5/9/18 that it has concluded its review of all data outputs and corresponding analyses from its successfully completed Phase 2 Brilacidin-OM trial (see NCT02324335) for the indication of decreasing the incidence of Severe Oral Mucositis (Severe OM) (WHO Grade ≥3) in Head and Neck Cancer (HNC) patients receiving chemoradiation.